Clarivate for Life Sciences & Healthcare’s Post

Are you attending CPHI in Milan this year? Don’t miss the upcoming webinar of Clarivate for Life Sciences & Healthcare! It’s a great opportunity to explore the latest trends, challenges, and opportunities in API manufacturing. #API #Manufacturing #CPHI #Milan #Clarivate

The changing dynamics of global API manufacturing - webinar imperdível para quem se preocupa com a cadeia de suprimentos global!

Our goal at Clarivate is to be the strategic partner to the industry, helping it as it makes some of the most strategic decisions. It was so exciting to see our LatAm team bring together the Life Sciences Industry, across Pharma and Chemical Manufacturers, as well as government and regulators to discuss how we can drive more innovation in Life Sciences in Latin America. Based on those discussions our team, with the help of our customers and partners, created this new whitepaper entitled, LATAM Summit: Navigating market and innovation opportunities. From market development to establishing public policies in LATAM markets, the report discusses how the independence of API imports, internationalization and incremental innovation can impact transformation in the region and shape the future.   Read more on how harmonizing efforts of industry, government and academia can drive effective change, success and innovation in LATAM, here: https://lnkd.in/eg34EyFh   #LATAM #pharma #API #clinicaltrials #innovation

The LATAM pharmaceutical market is poised to become a prime destination for domestic and international pharma companies, for clinical trials and for investment in local manufacturing sites. Read a new whitepaper on overcoming the barriers to success faced by the LATAM pharmaceutical industry. #LATAM #pharmaceutical #API #supplychain #clinicaltrials

Pharma production is forecast to experience healthy growth over the coming years 🧪📈 The main growth drivers are aging populations, emerging markets demand and new products, but some concerns around profitability exist 🤔 In the US and Europe, governments are pushing back against high drug costs with new pricing policies, which could limit revenues and lower incentives to invest in R&D. In emerging markets, quality standard issues remain a downside risk. Read about the latest developments and trends in the industry provided by our pharmaceutical sector experts 👉 https://brnw.ch/21wMw8p ✍️ Judy Ji ✍️ Rubén Del Río Hernández ✍️ Brady McKinney ✍️ Christian Bürger #pharmaceuticals #pharmaindustry #pharmaoutlook #pharceuticalsindustry #pharceuticalsoutlook

📈 Many pharmaceutical and life science companies are now taking a fresh look at their operating models. Next-Gen Global Business Services (GBS) can play a bigger role in how these companies reinvent work across the value chain. Discover how this innovative approach can help drive advanced business outcomes at lower costs and faster speeds. Very proud of the work our team is doing to support clients on this journey. #PharmaIndustry #NextGenGBS #Innovation

💡New Insights💡 The U.S. Inflation Reduction Act (IRA) and E.U.'s Joint Clinical Assessment (JCA) together constitute the most consequential legislative shift for the pharma industry in decades, requiring the industry to answer more challenging questions within shorter timeframes. Are companies underprepared? How might they adapt? In this new, joint article by Wickenstones Ltd and WittKieffer, the authors explore the challenges of the IRA and JCA and share insights for how pharma companies can expand their readiness in terms of: Culture, Competency and Capacity, Structure and Governance, and Market Access. The new legislation "pushes the pharmaceutical industry towards a more functionally integrated operating model. Fully integrated teams, which bring clinical development and regulatory affairs into closer alignment with market access from the beginning of asset development, lead to efficiencies and enhanced outcomes." In essence, the IRA and JCA bring "opportunities for the industry to evolve, adapt, and future-proof its operating model." #pharma #pharmaceuticalregulation #lifesciences #pharmaoperations

The recently published 'Draghi report' (The future of European competitiveness) requested by the European Commission, emphasizes the geostrategic significance of the Pharma sector in Europe and identifies the competitiveness gap as a critical issue for the sector, particularly due to the following reasons: • Lesser and fragmented public R&D investment in the EU. • Lesser private R&D investment in the EU and a weaker supporting environment. • A slow and complex EU regulatory framework. • The complex emergence of a European Health Data Space (EHDS-Koalition). This may become the most significant challenge for the Pharma industry in Europe in the upcoming years, and to address this issue effectively, the report suggests additional reforms and proposes a range of measures such as: - Maximise the impact of the EU Health Data Space - Streamline the set-up and management of multi-country trials in the EU - Expedite access to markets through coordinated action - Provide clear and timely guidance on the use of AI - Increase and focus public R&D investment in the EU as well as mobilise private R&D investment - Develop strategic international partnerships After reading the report, it is clear that both public institutions financial support and public-private partnerships are crucial for economic progress and competitiveness, particularly in vital industries like pharmaceuticals.

In the latest issue of #SpecialityChemicalsMagazine, Dr. Andrew Warmington reports from the Pharma Outsourcing Best Practices Panel at Chemspec Europe - Int. Exhibition for Fine & Speciality Chemicals. Read the full report here https://buff.ly/4eYPbIc #ChemspecEurope #PharmaOutsourcing #SpecialtyChemicals #IndustryInsights #ChemicalInnovation #BestPractices #PharmaNews